Dementia and Alzheimer Disease

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 21, 2024.

Neal K. Shah, CEO of CareYaya Health Technologies, discussed how sleep apnea and cognitive decline may be interrelated and disproportionately affecting minoritized populations.

A statistically significant dose-response correlation was observed, indicating that greater lifestyle changes led to better cognitive and functional outcomes in Alzheimer's patients.

In recent news, Otsuka has discontinued the development of AVP-786 following results from phase 3 trial assessing the treatment in patients with agitation related to Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on narcolepsy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 14, 2024.

John Dunlop, PhD, the chief scientific officer at Aliada Therapeutics, discussed the MODEL platform and its potential impact on therapeutic delivery for neurological conditions.

The president and CEO at Alzheon talked about the recent discoveries made in understanding the pathology of Alzheimer disease and the development of innovative therapies to potentially set the stage for more effective care. [WATCH TIME: 12 minutes]

In a pivotal, large-scale, phase 3 trial, donanemab met its primary end point, demonstrating more pronounced effects in patients with early-stage Alzheimer disease who had low/medium tau status.

Catch up on any of the neurology news headlines you may have missed over the course of May 2024, compiled all into one place by the NeurologyLive® team.

If the sBLA is approved, the clinical and biomarker benefits may be maintained through the once-monthly dosing regimen that is less burdensome and easier for patients and care partners to continue long-term.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on stroke and large hemispheric infarction.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 7, 2024.

Sharon Cohen, MD, and Marwan Sabbagh, MD, share their final thoughts on Alzheimer's disease and offer advice on strategies to reduce the risk of developing AD and slow the progression of the disease for those already affected.

Key opinion leaders discuss the Alzheimer's disease pipeline and the numerous disease-modifying therapies under investigation.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on amyotrophic lateral sclerosis (ALS).

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 31, 2024.

Medical experts discuss the application of ApoE gene polymorphism and copy number data in managing Alzheimer's disease, highlighting its relevance for individuals with a family history of AD, and symptomatic patients.

Panelists review the use of CSF and blood-based biomarkers in Alzheimer's disease, discussing the role of tau as a marker of neuronal injury and its utility in staging the progression of Alzheimer's disease.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

Neurology News Network. for the week ending May 25, 2024. [WATCH TIME: 4 minutes]

The professor and chair of rehabilitation medicine at UT Health San Antonio talked about the newly published guidelines for the assessment and management of spasticity in patients with neurological conditions. [WATCH TIME: 5 minutes]

The double-blind, placebo-controlled trial, which includes 2 dosing regimens of COYA 302, is expected to have topline data reported later this summer.

Adrienne Viscio, a 63-year-old patient diagnosed with primary progressive aphasia from CaringKind, talked about how she finds solace, engagement, and cognitive benefits through gardening.

The neurologist and neuro-oncologist at the Preston Robert Tisch Brain Tumor Center at Duke University provided clarity on a new analysis of the INDIGO study highlighting treatment benefits of vorasidenib in patients with IDH mutant grade 2 gliomas.

Bruce Leuchter, MD, a neuropsychiatrist and chief executive officer at Neurvati Neurosciences, provided insight on a recently published study showing that neurological diseases present the biggest global health threat.